AbbVie announced that the European Commission has approved Rinvoq® (upadacitinib) for the treatment of adults with moderately to severely active Crohn’s disease who have had an inadequate response, lost response or areintolerant to either conventional therapies or biologic agents. According to Abbvie, this is the seventh approved indication for Rinvoq® in the EU and is the only oral Janus Kinase inhibitor approved to treat adult patients with moderately to severely active Crohn’s disease.
The CHMP gave a positive opinion for Rinvoq® for the above indication on 27 February 2023.